Pieris Pharmaceuticals Announces Dosing of First Patient in Phase I Combination Trial for PRS-343 Plus Anti-PD-L1 Immunotherapy
pharmaceutical investing Pieris Pharmaceuticals Appoints Ingmar Bruns, M.D., Ph.D., as Vice President of Clinical Development
Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock
UPDATE - Critical Metals Corp (NASDAQ: CRML) Secures Another Significant Tanbreez Offtake Agreement for 15% of its Production with Leading U.S. Vertically Integrated Rare Earth Company, REalloys Inc.